Teva reports positive results in study for prevention of chronic and episodic migraine Major advance in the development of new treatment options for millions of patients
“Copaxone and Azilect came from Israeli universities. Why wouldn’t we tap into this incredible expertise and innovation of Israeli Universities to find the next jewels.”
“Today we can understand the processes resultingin disease and response to drugs in individual patients with greater precision than ever before.”
"Our collaboration with Teva will contribute greatly to the Korean pharmaceutical industry by supplying innovative medicines at affordable prices."
All News › Top News Oct 19, 2017 Teva to Highlight New Data in Multiple Sclerosis at Joint ECTRIMS – ACTRIMS Congress in Paris Learn More Share Top News Oct 17, 2017 Teva Announces Submission of Biologics License Application for Fremanezumab to the U.S. FDA Learn More Share Top News Oct 10, 2017 Teva to Report Third Quarter 2017 Financial Results on November 2, 2017 Learn More Share Top News Oct 5, 2017 Teva Announces tomy’s Award Winner at Oncology Satellite Symposium During the 7th International Symposium on Acute Promyelocytic Leukemia (APL) in Rome, Italy Learn More Share Top News Oct 4, 2017 Teva Comments on Anticipated At-Risk U.S. Launch of Generic Glatiramer Acetate 40mg/mL and Launch of Generic Glatiramer Acetate 20mg/mL Learn More Share
Top News Oct 19, 2017 Teva to Highlight New Data in Multiple Sclerosis at Joint ECTRIMS – ACTRIMS Congress in Paris Learn More
Top News Oct 17, 2017 Teva Announces Submission of Biologics License Application for Fremanezumab to the U.S. FDA Learn More
Top News Oct 10, 2017 Teva to Report Third Quarter 2017 Financial Results on November 2, 2017 Learn More
Top News Oct 5, 2017 Teva Announces tomy’s Award Winner at Oncology Satellite Symposium During the 7th International Symposium on Acute Promyelocytic Leukemia (APL) in Rome, Italy Learn More
Top News Oct 4, 2017 Teva Comments on Anticipated At-Risk U.S. Launch of Generic Glatiramer Acetate 40mg/mL and Launch of Generic Glatiramer Acetate 20mg/mL Learn More
TAPI Launches Upgraded Customer Portal! TAPI has launched its upgraded customer portal, TAPI Online. This exciting new portal provides full support for API projects, including a range of tools and a comprehensive API document library. Discover more
TAPI has launched its upgraded customer portal, TAPI Online. This exciting new portal provides full support for API projects, including a range of tools and a comprehensive API document library.
Teva’s Healthcare Heroes Teva’s Healthcare Heroes Awards program honors the memory of Richard Egosi, former Teva group EVP and chief legal officer Discover more
Teva’s Healthcare Heroes Awards program honors the memory of Richard Egosi, former Teva group EVP and chief legal officer
How Our Uniqueness Creates Healthcare Confidence Around the world, people know that our ultimate goal is their health and well-being. Find out how we do it:
Around the world, people know that our ultimate goal is their health and well-being. Find out how we do it: